Reports

August 2014

Identifying the Benefits and Risks of Emerging Treatment for Idiopathic Pulmonary Fibrosis: A Qualitative Study

July 2014

Personalized Medicine and Responsible Access to Pain Medication

September 2013

Measuring Responsibility

March 2013

In Praise of a BRAT

October 2012

Fixing Drug Shortages

June 2012

From Promise to Performance

June 2012

Promoting Innovation And Health

June 2012

Government Detailing

April 2012

Cough Medicine Consumer Insights National Survey

February 2012

FDLI's Food and Drug Policy Forum

January 2012

Fewer Drugs, Shorter Lives, Less Prosperity: The Impact of Comparative Effectiveness Research on Health and Wealth

December 2011

PDUFA without the Politics

November 2011

Fewer Drugs, Shorter Lives, Less Prosperity: The Impact of Comparative Effectiveness Research on Health and Wealth

November 2011

The Danger of Shorting Drug Shortages

November 2011

Noncommunicable Diseases in Developing Countries

September 2011

CER: Pharmaceutical Innovation, Health and Longevity

May 2011

Shorter Lives, Less Prosperity: The Impacts of CER

May 2011

Innovation Nation

May 2011

Communicating Cost-Think

March 2011

The coronavirus could help pharma reset its reputation in Washington

The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington.... Read more

STAT
10/17/2024 12:00 AM

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Differing philosophies within and outside of government could doom the hub... Read more

The Washington Times
07/02/2024 12:00 AM

Tort bar’s newest collateral damage: Preterm babies

Lawsuits allege links between intestinal disease, infant formula and human milk fortifiers... Read more

RECENT NEWS

The coronavirus could help pharma reset its reputation in Washington

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Tort bar’s newest collateral damage: Preterm babies

DRUGWONKS BLOG

RESEARCH ISSUES